Abcam, ab258342, Human CBLB knockout HeLa cell lysate

Size: 1Kit
CBLB KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon6.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon6.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-CBLB, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CBLB also known as Cbl-b or Casitas B-lineage lymphoma-b is an E3 ubiquitin-protein ligase with a mass of approximately 120 kDa. CBLB is required for the regulation of protein degradation and is involved in transferring ubiquitin to target proteins. It is expressed in multiple tissues including the immune cells such as T cells and B cells. This protein contains several functional domains that facilitate interaction with other proteins allowing it to influence various signaling pathways.
Biological function summary
CBLB plays a critical role in immune regulation and is part of the ubiquitin-proteasome system. As a member of the CBL protein family it interacts with several other proteins to form a complex that determines its function. This complex mediates signal transduction and maintains immune homeostasis efforting its regulatory influence over immune cell activation and avoiding excessive immune responses.
Pathways
CBLB integrates into intracellular signaling involving the T-cell receptor (TCR) and B-cell receptor (BCR) pathways. It modulates downstream signaling by finetuning protein levels and activity interfacing with related proteins such as ZAP70 and Syk. By controlling signal thresholds it ensures proper immune responses and prevents autoimmunity maintaining the balance in signal transduction processes.
Altered CBLB activity is associated with autoimmune diseases and certain cancers such as lymphoma. Its dysfunction can lead to improper regulation of immune responses allowing for unchecked immune activation or proliferation of cancer cells. CBLB interacts with other critical proteins like ITK in T cells influencing the development or progression of these diseases by affecting cell signaling dynamics. Understanding CBLB's role could support therapeutic interventions to modulate immune responses effectively.